



**NATIONAL HEMOPHILIA FOUNDATION**  
*for all bleeding disorders*

MASAC Document #153

**MASAC Recommendation Concerning Reimbursement for Recombinant Clotting Factor Concentrates**

The following document was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on November 8, 2003, and adopted by the NHF Board of Directors on November 9, 2003.

[View Printer-Friendly PDF Version >>](#)

There are now available several different recombinant factor products for the treatment of hemophilia. There are specific considerations in prescribing a product for any individual patient.

Therefore MASAC recommends that insurance companies and other third-party payers such as Medicaid, Medicare, CMS, etc. cover whichever recombinant factor product is prescribed by the patient's treating physician.

**Disclaimer**

The information contained on the NHF web site is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.

All information and content on this web site are protected by copyright. All rights are reserved. Users are prohibited from modifying, copying, distributing, transmitting, displaying, publishing, selling, licensing, creating derivative works, or using any information available on or through the site for commercial or public purposes.

Copyright 2003 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Director of Communications at 1-800-42-HANDI or visit the NHF website at [www.hemophilia.org](http://www.hemophilia.org).

